Back to top

BeOne Medicines (ONC) Investors Track New Data from BeiGene’s Chronic Urticaria Trial

BeOne Medicines ($ONC) announced an update on their ongoing clinical study. BeOne Medicines (ONC) investors are watching a new update on a BeiGene ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

BeOne Medicines Ltd. - Sponsored ADR (ONC)